CVI-LM001
Phase 2- Indications
- Hypercholesterolemia
Company intelligence / Profile preview
CVI Pharmaceuticals
Shanghai, Shanghai Shi, Chinacvipharma.com ↗
- Ownership
- Private
- Employees
- ~5
- Development stage
- Phase 2
01
Overview
CVI Pharmaceuticals develops first-in-class, oral small-molecule therapies targeting cardiometabolic diseases. Its lead candidate, CVI-LM001, a novel PCSK9 modulator for hypercholesterolemia, has reached phase 2 proof-of-concept trials. The company also pursues programs in NAFLD/NASH and other metabolic indications using small molecule approaches.
- Therapeutic areas
- GastroenterologyCardiovascular
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on CVI Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CVI Pharmaceuticals.